- Details
- Description
- 
                                            Packaging Size30c/Bottle
- 
                                            Strength15mg
- 
                                            CompositonGolidocitinib
- 
                                            TreatmentAdult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL)
- 
                                            FormCapsule
- 
                                            Brand高瑞哲
- 
                                            Quantity Unit0.15g*30c/Box
- 
                                            ManufacturerDizal Pharma, China
Golidocitinib (DZD4205) is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).
- Golidocitinib sold under the brand name 高瑞哲® in china.
 
                     
                             
                         
                                     
                                     
                                     
                                     
                                     
                                             
                                             
                                             
                                             
                             
                             
                            